161 related articles for article (PubMed ID: 12826649)
21. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.
Herold M; Dölken G; Fiedler F; Franke A; Freund M; Helbig W; Pasold R
Ann Hematol; 2003 Feb; 82(2):77-9. PubMed ID: 12601483
[No Abstract] [Full Text] [Related]
22. Progress in immunotherapy rituximab.
El-Habbash MM; Alwindi AM
Saudi Med J; 2007 Nov; 28(11):1635-44. PubMed ID: 17965780
[TBL] [Abstract][Full Text] [Related]
23. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
O'Connor OA; Portlock C; Moskowitz C; Straus D; Hamlin P; Stubblefield M; Dumetrescu O; Colevas AD; Grant B; Zelenetz A
Br J Haematol; 2008 Oct; 143(2):201-9. PubMed ID: 18691173
[TBL] [Abstract][Full Text] [Related]
24. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
25. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
26. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
[TBL] [Abstract][Full Text] [Related]
27. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
[TBL] [Abstract][Full Text] [Related]
28. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
29. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
30. [A case of malignant lymphoma of the thyroid accompanied by interstitial pneumonitis during radiation therapy after systemic chemotherapy].
Doi M; Hisada Y; Namba R; Nakata Y; Saika Y; Shimizu T; Sueyoshi K; Kawai T; Narabayashi I
Gan To Kagaku Ryoho; 1994 Feb; 21(2):269-72. PubMed ID: 8311501
[TBL] [Abstract][Full Text] [Related]
31. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
Akhtar S; Maghfoor I
J Clin Oncol; 2005 Sep; 23(25):6261; author reply 6262. PubMed ID: 16135496
[No Abstract] [Full Text] [Related]
32. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
33. Acute respiratory failure associated with cladribine pneumonitis.
Feenstra JF; Hickey BP; Blackwell EA
Intern Med J; 2004; 34(9-10):583-4. PubMed ID: 15482276
[No Abstract] [Full Text] [Related]
34. Interstitial pneumonitis associated with infliximab therapy.
Villeneuve E; St-Pierre A; Haraoui B
J Rheumatol; 2006 Jun; 33(6):1189-93. PubMed ID: 16622902
[TBL] [Abstract][Full Text] [Related]
35. [Interstitial pneumonia in patients treated with VACOP-B therapy for malignant lymphoma].
Sakai C; Goto S; Nakaseko C; Kumagai K; Takagi T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):423-6. PubMed ID: 9492839
[No Abstract] [Full Text] [Related]
36. [Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma].
Mayer J; Navrátil M; Vásová J; Vorlícek J
Vnitr Lek; 2001 Sep; 47 Suppl 1():57-62. PubMed ID: 11693064
[TBL] [Abstract][Full Text] [Related]
37. Rituximab-induced interstitial lung disease: case report and literature review.
Zayen A; Rais H; Rifi H; Ouarda M; Afrit M; Cherif A; Mezline A
Pharmacology; 2011; 87(5-6):318-20. PubMed ID: 21613805
[TBL] [Abstract][Full Text] [Related]
38. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma.
Kosits C; Callaghan M
Oncol Nurs Forum; 2000; 27(1):51-9. PubMed ID: 10660923
[TBL] [Abstract][Full Text] [Related]
39. Rituximab: gastrointestinal perforation.
Prescrire Int; 2007 Oct; 16(91):201. PubMed ID: 17929385
[No Abstract] [Full Text] [Related]
40. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
